Free from its search giant parent, biotech Verily takes a more modest approach. “I hear that, and it screams privacy”
The first of 10,000 volunteers will soon walk into labs at Stanford and Duke to subject themselves to two days of tests. Each will provide a blood sample for DNA sequencing and a stool sample for a gut bacteria scan, get a chest X-ray and an electrocardiogram, and take a psychological assessment. Participants will be asked if they’re willing to share electronic health records and insurance claims. They may also be asked to share records of phone, text, and social media activity. All will go home with a special wristwatch meant to track their heart rate, sweat, and number of steps for the next four years.
The study—called Baseline, as in a starting point—opened on 19 April. It marks the first serious public test for Verily Life Sciences LLC, formerly Google Life Sciences, the search company’s biotech arm. While Verily has separated from Google’s internet business within the Alphabet Inc. holding company, it’s following its former parent’s approach to data by collecting and organising as much information as it can about our bodies—data it hopes will guide better health decisions.
Baseline tests alone will likely run at least $300 million before administrative costs, says Sam Gambhir, the professor running Stanford’s part of it. (Verily declined to comment.) While that sounds ambitious, it’s much more modest than the missions Verily promoted when it was part of Google. Just five years ago the division promised projects such as glucose-monitoring contact lenses and all-in-one medical scanners; those remain in the lab. Former employees say the internal code name for the life sciences division was Panacea—cureall. No one calls it that anymore.
Denne historien er fra May 01, 2017-utgaven av Bloomberg Businessweek Middle East.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra May 01, 2017-utgaven av Bloomberg Businessweek Middle East.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Golfing With The Enemy
Did Donald Trump's executives violate the Cuban embargo?
Super-Rich Syrians Wait for War's End
Actor, author, playwright. Gill Pringle tries her hand at unravelling the mystery behind this enigmatic multi-hyphenate
Pam Codispoti
The mastermind behind the industry-shaping Chase Sapphire Reserve Card sets her sights on banking
This Time It's The Economy
President Rouhani’s budget sets offprotests from people angry about unemployment and inflation
Saudi Prince Counts On Support Of Citizens
State-worker salary increases appeal to the people, but policy may throw the budget off track
Stalin's Legacy Is Choking The Ukrainian Economy
The government has resisted pressure to lift a ban on land sales, despite pressure from the IMF and investors
Catastrophe Bonds Survive A Stormy Year
The turbulence of 2017 couldn’t destroy a market for betting against disasters
Riding The West Bank's Credit Boom
Increased consumer lending is creating a bubble in the West Bank
You'd Be Crazy To Buy Pizza With Bitcoin
Speculative fervour makes the cryptocurrency clumsy for commerce
What If The President Loses His Party?
Trump has to figure out a way to work with Republicans in Congress, or the global economy may be at stake